1
|
Liu Y, Ai H. Comprehensive insights into human papillomavirus and cervical cancer: Pathophysiology, screening, and vaccination strategies. Biochim Biophys Acta Rev Cancer 2024; 1879:189192. [PMID: 39349261 DOI: 10.1016/j.bbcan.2024.189192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2024] [Revised: 09/07/2024] [Accepted: 09/23/2024] [Indexed: 10/02/2024]
Abstract
This article provides an in-depth review of the Human Papillomavirus (HPV), a predominant etiological factor in cervical cancer, exploring its pathophysiology, epidemiology, and mechanisms of oncogenesis. We examine the role of proteins, DNA methylation markers, and non-coding RNAs as predictive biomarkers in cervical cancer, highlighting their potential in refining diagnostic and prognostic practices. The evolution and efficacy of cervical cancer screening methods, including the Papanicolaou smear, HPV testing, cytology and HPV test, and colposcopy techniques, are critically analyzed. Furthermore, the article delves into the current landscape and future prospects of prophylactic HPV vaccines and therapeutic vaccines, underscoring their significance in the prevention and potential treatment of HPV-related diseases. This comprehensive review aims to synthesize recent advances and ongoing challenges in the field, providing a foundation for future research and clinical strategies in the prevention and management of cervical cancer.
Collapse
Affiliation(s)
- Ying Liu
- Liaoning Provincial Key Laboratory of Follicular Development and Reproductive Health, Jinzhou Medical University, 2, Section 5, Heping Road, Linghe, Jinzhou, Liaoning 121000, PR China
| | - Hao Ai
- Liaoning Provincial Key Laboratory of Follicular Development and Reproductive Health, Jinzhou Medical University, 2, Section 5, Heping Road, Linghe, Jinzhou, Liaoning 121000, PR China.
| |
Collapse
|
2
|
Roman C, Andrade D, Hernández Y, Salazar ZK, Espinosa L, Campoverde E, Guallaizaca L, Merchán M, Sarmiento M, Brenner J. Biological, demographic, and health factors associated with HPV infection in Ecuadorian women. Front Public Health 2023; 11:1158270. [PMID: 37397749 PMCID: PMC10311495 DOI: 10.3389/fpubh.2023.1158270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 05/11/2023] [Indexed: 07/04/2023] Open
Abstract
Objectives The study aims to identify the correlation between human papillomavirus (HPV) infection and sociodemographic and sexual reproductive health factors in Ecuadorian women from March to August 2019. Methods 120 women were randomly selected from two gynecological clinics to complete a questionnaire and provide a biospecimen. PCR-Hybridization was used to genotype 37 HPV serotypes in samples obtained by endo-cervical brushing for liquid-based cytology. Sociodemographic and sexual health data were collected through a validated questionnaire during a medical consultation. Mathematical modeling of HPV infection was done using bivariate logistic regression. Results 65.0% of the women sampled had an HPV infection; 74.3% of these women had co-infections with other HPV genotypes. Out of the women who were HPV positive, 75.6% were diagnosed with high-risk genotypes from HPV strains 18, 35, 52, and 66. Parity, immunosuppression, and use of oral contraception/intrauterine devices (IUDs) were identified as associated variables. The explanatory model had a sensitivity of 89.5% and a specificity of 73.8%. Conclusion The predominant strains of HPV among Ecuadorian women are diverse. The risk of HPV infection is a complex phenomenon where biological and psychosocial variables are integrated into a model. In populations with limited access to health services, low socioeconomic status, and negative sociocultural beliefs about sexually transmitted infections (STIs), surveys can be used as a pre-screening step for HPV infections. The diagnostic value of the model should be tested in multicenter studies that include women from all over the country.
Collapse
Affiliation(s)
- Carlos Roman
- Diagnostic Department, MEDsan, Inc., Saint Petersburg, FL, United States
| | - Diego Andrade
- Investigation Center for Health, Academic Unit of Health and Wellness, Catholic University of Cuenca (UCACUE), Cuenca, Ecuador
| | - Yenima Hernández
- Department of Mental Health, The Angels Mental Health Community, Tampa, FL, United States
| | - Zoila K. Salazar
- Investigation Center for Health, Academic Unit of Health and Wellness, Catholic University of Cuenca (UCACUE), Cuenca, Ecuador
- Medical Center Association for the Well-being of the Ecuadorian Family (APROFE), Cuenca, Ecuador
| | - Lizette Espinosa
- Investigation Center for Health, Academic Unit of Health and Wellness, Catholic University of Cuenca (UCACUE), Cuenca, Ecuador
| | - Erika Campoverde
- Investigation Center for Health, Academic Unit of Health and Wellness, Catholic University of Cuenca (UCACUE), Cuenca, Ecuador
| | - Lourdes Guallaizaca
- Investigation Center for Health, Academic Unit of Health and Wellness, Catholic University of Cuenca (UCACUE), Cuenca, Ecuador
| | - María Merchán
- Investigation Center for Health, Academic Unit of Health and Wellness, Catholic University of Cuenca (UCACUE), Cuenca, Ecuador
| | - Miriam Sarmiento
- Obstetrics Department, San Juan de Dios Hospital, Cuenca, Ecuador
| | - Jonathan Brenner
- Diagnostic Department, MEDsan, Inc., Saint Petersburg, FL, United States
| |
Collapse
|
3
|
HPV Prevalence in Pregnancy with Demographic and Socioeconomic Considerations. INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY 2023. [DOI: 10.1007/s40944-022-00701-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
4
|
Sulthanudeen S, Imran PM, Selvakumaran M, Kubaib A. Novel acridone derivatives performed using DFT, including design, synthesis, characterization and anti-oxidant and anti-mitotic activity screening. RESULTS IN CHEMISTRY 2022. [DOI: 10.1016/j.rechem.2022.100753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
5
|
Diagnosis of Early Cervical Cancer with a Multimodal Magnetic Resonance Image under the Artificial Intelligence Algorithm. CONTRAST MEDIA & MOLECULAR IMAGING 2022; 2022:6495309. [PMID: 35386728 PMCID: PMC8967556 DOI: 10.1155/2022/6495309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Revised: 02/18/2022] [Accepted: 02/21/2022] [Indexed: 12/03/2022]
Abstract
This research was conducted to explore the value of multimodal magnetic resonance imaging (MRI) based on the alternating direction algorithm in the diagnosis of early cervical cancer. 64 patients diagnosed with early cervical cancer clinicopathologically were included, and according to the examination methods, they were divided into A group with conventional multimodal MRI examination and B group with the multimodal MRI examination under the alternating direction algorithm. The diagnostic results of two types of multimodal MRI for early cervical cancer staging were compared with the results of clinicopathological examination to judge the application value in the early diagnosis of cervical cancer. The results showed that in the 6 randomly selected samples of early cervical cancer patients, the peak signal-to-noise ratio (PSNR) and structural similarity image measurement (SSIM) of multimodal MRI images under the alternating direction algorithm were significantly higher than those of conventional multimodal MRI images and the image reconstruction was clearer under this algorithm. By comparing MRI multimodal staging, statistical analysis showed that the staging accuracy of B group was 75%, while that of A group was only 59.38%. For the results of postoperative medical examinations, the examination consistency of B group was better than that of A group, with a statistically significant difference (P < 0.05). The area under the receiver operating characteristic (ROC) curve (AUC) of B group was larger than that of A group; thus, sensitivity was improved and misdiagnosis was reduced significantly. Multimodal MRI under the alternating direction algorithm was superior to conventional multimodal MRI examination in the diagnosis of early cervical cancer, as the lesions were displayed more clearly, which was conducive to the detection rate of small lesions and the staging accuracy. Therefore, it could be used as an ideal MRI method for the assistant diagnosis of cervical cancer staging.
Collapse
|
6
|
Tekalegn Y, Sahiledengle B, Woldeyohannes D, Atlaw D, Degno S, Desta F, Bekele K, Aseffa T, Gezahegn H, Kene C. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. WOMEN'S HEALTH (LONDON, ENGLAND) 2022; 18:17455065221075904. [PMID: 35114865 PMCID: PMC8819811 DOI: 10.1177/17455065221075904] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Background: Cervical cancer is the fourth most common cancer among women. High parity has
long been suspected with an increased risk of cervical cancer. Evidence from
the existing epidemiological studies regarding the association between
parity and cervical cancer is variable and inconsistent. Therefore, the
objective of this systematic review and meta-analysis was to synthesize the
best available evidence on the epidemiological association between parity
and cervical cancer. Methods: Case–control studies reporting the association between parity and cervical
cancer were systematically searched in databases like MEDLINE/PubMed,
HINARI, Google scholar, Science direct, and Cochrane Libraries. All studies
fulfilling the inclusion criteria and published between 2000 and 7 March
2020 were included in this meta-analysis. This study reported according to
PRISMA guideline. Cochran’s Q-statistics and
I2 tests were performed to assess
heterogeneity among included studies. Egger’s regression analysis was
performed to assess publication bias. A random-effect meta-analysis model
was used to compute pooled odds ratio of the association between parity and
cervical cancer. Results: A total of 6685 participants (3227 patients and 3458 controls) were
incorporated in the 12 studies included in this meta-analysis. The
meta-analysis revealed that women with high parity had 2.65 times higher
odds of developing cervical cancer compared to their counterparts (odds
ratio = 2.65, 95% confidence interval = 2.08–3.38). Conclusion: High parity is positively associated with cervical cancer. Strong
epidemiological studies are recommended to further explore the mechanisms
and role of parity in the causation of cervical cancer.
Collapse
Affiliation(s)
- Yohannes Tekalegn
- Department of Public Health, School of Health Sciences, Goba Referral Hospital, Madda Walabu University, Goba, Ethiopia
| | - Biniyam Sahiledengle
- Department of Public Health, School of Health Sciences, Goba Referral Hospital, Madda Walabu University, Goba, Ethiopia
| | - Demelash Woldeyohannes
- Department of Public Health, College of Medicine and Health Sciences, Wachemo University, Hosaena, Ethiopia
| | - Daniel Atlaw
- Department of Human Anatomy, School of Medicine, Goba Referral Hospital, Madda Walabu University, Goba, Ethiopia
| | - Sisay Degno
- Department of Human Anatomy, School of Medicine, Goba Referral Hospital, Madda Walabu University, Goba, Ethiopia
| | - Fikreab Desta
- Department of Public Health, School of Health Sciences, Goba Referral Hospital, Madda Walabu University, Goba, Ethiopia
| | - Kebebe Bekele
- Department of Surgery, School of Medicine, Goba Referral Hospital, Madda Walabu University, Goba, Ethiopia
| | - Tesfaye Aseffa
- Department of Nursing, School of Health Sciences, Goba Referral Hospital, Madda Walabu University, Goba, Ethiopia
| | - Habtamu Gezahegn
- Department of Human Physiology, School of Medicine, Goba Referral Hospital, Madda Walabu University, Goba, Ethiopia
| | - Chala Kene
- Department of Midwifery, School of Health Sciences, Goba Referral Hospital, Madda Walabu University, Goba, Ethiopia
| |
Collapse
|
7
|
Utami TW, Kusuma F, Winarto H, Anggraeni TD, Peters AAW, Spaans V, Humairah IR, Ardiani V, Utomo ARH, Dahlan MS. Tobacco use and its association with HPV infection in normal uterine cervix: A study from a Sustainable Development Goals perspective. Tob Induc Dis 2021; 19:64. [PMID: 34413719 PMCID: PMC8340940 DOI: 10.18332/tid/140093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 06/22/2021] [Accepted: 07/08/2021] [Indexed: 11/24/2022] Open
Abstract
INTRODUCTION To achieve the Sustainable Development Goals (SDGs) target 2030, the United Nations (UN) endorsed tobacco use reduction, which is essential in decreasing unnecessary deaths caused by tobacco-induced disease. This study investigates the association between tobacco use and Human Papillomavirus (HPV) infection in clinically normal uterine cervix populations from the SDGs perspective. METHODS This study is a 7-year cross-sectional study of a clinically normal uterine cervix population, based on negative Visual Inspection of Acetic Acid (VIA). Subjects were recruited consecutively from the medical records of several public and private health providers in Jakarta. The Statistical Product and Service Solutions (SPSS) for Windows version 20.0 were used to analyze the data. RESULTS A total of 1397 negative VIA subjects were collected, consisting of 4.9% (69/1397) tobacco users, and 95.1% (1328/1397) non-users. HPV-DNA positive were 4.3% (3/69) in the tobacco user group and 3.7% (49/1328) in the non-user group. Statistical analysis showed unadjusted OR was 1.19 (95% CI: 0.36–3.91, p=0.778) and adjusted OR was 1.18 (95% CI: 0.36–3.89, p=0.786). High-risk HPV (hrHPV) infections of tobacco and non-tobacco users’ groups were found in 2/3 and 27/49 (55.1%), respectively. CONCLUSIONS This study showed an insignificant statistical association between tobacco use and HPV infection in normal uterine cervix. However, the proportion of hrHPV infection was higher in tobacco users than non-users. From the SDGs perspective, cervical cancer is closely related to tobacco use and poverty. Further study is needed to support this result and evaluate other co-factor role-related cervical cancer history to achieve SDGs in 2030.
Collapse
Affiliation(s)
- Tofan W Utami
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Universitas Indonesia, Central Jakarta, Indonesia
| | - Fitriyadi Kusuma
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Universitas Indonesia, Central Jakarta, Indonesia
| | - Hariyono Winarto
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Universitas Indonesia, Central Jakarta, Indonesia
| | - Tricia D Anggraeni
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Universitas Indonesia, Central Jakarta, Indonesia
| | | | - Vivian Spaans
- Department of Pathology, Leiden University Medical Center, Leiden, Netherlands
| | - Inas R Humairah
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Universitas Indonesia, Central Jakarta, Indonesia
| | - Vani Ardiani
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Universitas Indonesia, Central Jakarta, Indonesia
| | - Ahmad R H Utomo
- Department of Research and Development, Dharmais Cancer Hospital, West Jakarta, Indonesia
| | - Muhamad S Dahlan
- Clinical Epidemiology Department, Epidemiologi Indonesia, East Jakarta, Indonesia
| |
Collapse
|
8
|
Attademo L, Tuninetti V, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Valabrega G, Musacchio L, Setola SV, Piccirillo P, Califano D, Spina A, Losito S, Greggi S, Pignata S. Immunotherapy in cervix cancer. Cancer Treat Rev 2020; 90:102088. [PMID: 32827839 DOI: 10.1016/j.ctrv.2020.102088] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 07/29/2020] [Accepted: 07/31/2020] [Indexed: 12/18/2022]
Abstract
The treatment approach to cervix cancer has remained unchanged for several decades and new therapeutic strategies are now required to improve outcomes, as the prognosis is still poor. In the last years, a better understanding of HPV tumor-host immune system interactions and the development of new therapeutics targeting immune checkpoints generated interest in the use of immunotherapy in cervix cancer. Preliminary phase I-II trials demonstrated the efficacy, the duration of responses and the manageable safety of this approach. Currently, many phase II and III studies are ongoing in both locally advanced and metastatic cervical cancer, assessing immunotherapy as a single agent or in combination with chemotherapy and radiotherapy. We reviewed the published data and the therapeutic implications of the most promising novel immunotherapeutic agents under investigation in cervix cancer.
Collapse
Affiliation(s)
- Laura Attademo
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Valentina Tuninetti
- Candiolo Cancer Institute, FPO-IRCCS Candiolo (TO), Italy; Department of Oncology, University of Torino, Italy.
| | - Carmela Pisano
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Sabrina Chiara Cecere
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Marilena Di Napoli
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Rosa Tambaro
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Giorgio Valabrega
- Candiolo Cancer Institute, FPO-IRCCS Candiolo (TO), Italy; Department of Oncology, University of Torino, Italy.
| | - Lucia Musacchio
- Department of Maternal and Child Health and Urological Sciences, University "Sapienza", Policlinico Umberto I, Rome, Italy.
| | | | - Patrizia Piccirillo
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Daniela Califano
- Functional Genomic Unit, Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Anna Spina
- Functional Genomic Unit, Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Simona Losito
- Surgical Pathology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Stefano Greggi
- Gynecologic Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| | - Sandro Pignata
- Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
| |
Collapse
|